nsc-366140 and Carcinoma--Squamous-Cell

The Gynecologic Oncology Group performed a phase II study to determine the response rate to pyrazoloacridine (PZA) in patients with advanced, persistent or recurrent squamous carcinoma of the cervix.. PZA was administered intravenously over 3 h every 3 weeks. A dose of 760 mg/m(2) was given to the first 11 patients and was reduced to 560 mg/m(2) for subsequent patients. The dose reduction was undertaken because of unexpected severe neutropenia among the initial patients.. Among 24 evaluable patients, 21 of whom had prior chemotherapy, there was one, brief, complete response (4.2%) and no partial responses. The major toxicity was neutropenia.. PZA at the dose and schedule employed, has insignificant activity in this population.

Topics: Acridines; Adult; Aged; Carcinoma, Squamous Cell; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Intercalating Agents; Middle Aged; Neutropenia; Nucleic Acid Synthesis Inhibitors; Pyrazoles; Remission Induction; Salvage Therapy; Treatment Outcome; Uterine Cervical Neoplasms; Vomiting

The Gynecologic Oncology Group performed a Phase II study to determine the response rate of Pyrazoloacridine (PZA) in patients with advanced, persistent or recurrent squamous carcinoma of the cervix.. PZA was administered at a dose of 750 mg/m2 intravenously over three hours every three weeks.. Among 21 evaluable patients, there were no complete and one (4.2%) partial response. The major toxicities were hematologic.. PZA at the dose and schedule employed has insignificant activity in this population.

Topics: Acridines; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Humans; Middle Aged; Pyrazoles; Treatment Outcome; Uterine Cervical Neoplasms